MB
Maria R. Baer
Highly rated in
29
conditions

Dr. Maria R. Baer

University Of Maryland Medical Center
Baltimore, MD
Highly rated in
29
conditions
Specialties:Hematology Oncology | Hematology
Experience:44 Years
Age:71
Clinical Trials:Currently Recruiting for 4 Trials
Accepts:New PatientsMedicare
Highly rated in
29
conditions
About|Expertise|Insurance|Location|Research
Areas of Expertise

Many doctors have expertise treating multiple conditions. MediFind uses a variety of data sources to determine what conditions a doctor treats and their level of experience.

View 38 More Conditions +
Check Dr. Maria R. Baer's experience treating your condition:
About Dr. Maria R. Baer

Maria Baer is a Hematologist Oncology specialist and a Hematologist in Baltimore, Maryland. Baer has been practicing medicine for over 44 years and is highly rated in 29 conditions, according to our data. Her top areas of expertise are Acute Myeloid Leukemia (AML), Acute Myeloblastic Leukemia with Maturation, Acute Myeloblastic Leukemia without Maturation, Bone Marrow Aspiration, and Bone Marrow Transplant. She is licensed to treat patients in Maryland. Baer is currently accepting new patients.

Her clinical research consists of co-authoring 197 peer reviewed articles and participating in 19 clinical trials in the past 15 years.

Insurance

MediFind strives to display the most accurate insurance information for every doctor. If you do not see your insurance listed for Dr. Maria R. Baer it is best to call her office and ask if your insurance is accepted.

Accepts Medicare

Dr. Maria R. Baer accepts the following insurance:

  •  Ambetter
  •  CareFirst
Call to see if your plan is accepted.
Locations
22 S Greene St, Baltimore, MD 21201
Other Locations
10 N Greene St, Baltimore, MD 21201
Background & Education
Graduate Institution
Johns Hopkins University School Of Medicine, 1979
Specialties
Hematology Oncology
Hematology
Licenses
Internal Medicine in MD
Hospital Affiliations
UM Shore Medical Center At Easton
University Of Maryland Medical Center
Baltimore VA Medical Center
Languages Spoken
English
French
Spanish
Gender
Female
Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Doctors who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

19 Clinical Trials
A Phase II Study of Inotuzumab Ozogamicin Followed by Blinatumomab for Ph-Negative CD22-Positive B-Lineage Acute Lymphoblastic Leukemia in Newly Diagnosed Older Adults or Adults With Relapsed or Refractory Disease
Enrollment Status: Recruiting
Publish Date: December 09, 2022
Intervention Type: Biological
Study Drugs: BlinatumomabInotuzumab
Study Phase: Phase 2
A Phase 3, Randomized, Open-label, Multicenter Study Comparing Ponatinib Versus Imatinib, Administered in Combination With Reduced-Intensity Chemotherapy, in Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL)
Enrollment Status: Recruiting
Publish Date: November 10, 2022
Intervention Type: Drug
Study Drugs: PonatinibImatinibVincristineDexamethasoneCytarabineMethotrexatePrednisone
Study Phase: Phase 3
A Master Protocol for Biomarker-Based Treatment of AML (The Beat AML Trial)
Enrollment Status: Recruiting
Publish Date: October 19, 2022
Intervention Type: Drug, Biological, Other
Study Drugs: SamalizumabBI-836858DaunorubicinCytarabineAzacitidineAG-221EntospletinibDecitabinePevonedistatAG-120GilteritinibAZD5153VenetoclaxTP-0903AZD5991
Study Phase: Phase 1/Phase 2
A Phase Ib Study of the Pharmacokinetics, Safety and Efficacy of Orally Administered HQP1351 in Subjects With Refractory Chronic Myeloid Leukemia (CML) and Ph+ Acute Lymphoblastic Leukemia (Ph+ ALL)
Enrollment Status: Recruiting
Publish Date: July 12, 2022
Intervention Type: Drug
Study Drug: Ascentage HQP1351 Inhibitor
Study Phase: Phase 1
A Phase III, International, Randomized, Controlled Study of Rigosertib Versus Physician's Choice of Treatment in Patients With Myelodysplastic Syndrome After Failure of a Hypomethylating Agent
Enrollment Status: Terminated
Publish Date: September 26, 2022
Intervention Type: Drug
Study Drug: Rigosertib
Study Phase: Phase 3
A Phase III Randomized Trial of Blinatumomab for Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia in Adults
Enrollment Status: Active, not recruiting
Publish Date: September 16, 2022
Intervention Type: Drug, Biological, Other, Procedure
Study Drugs: BlinatumomabCyclophosphamideCytarabineDaunorubicinDaunorubicin HydrochlorideDexamethasoneEtoposideMercaptopurineMethotrexatePegaspargasePrednisoneRituximabVincristineVincristine Sulfate
Study Phase: Phase 3
A Phase II Study of Blinatumomab and POMP (Prednisone, Vincristine, Methotrexate, 6-Mercaptopurine) for Patients ≥ 65 Years of Age With Newly Diagnosed Philadelphia-Chromosome Negative (Ph-) Acute Lymphoblastic Leukemia (ALL) and of Dasatinib, Prednisone and Blinatumomab for Patients ≥ 65 Years of Age With Newly Diagnosed Philadelphia-Chromosome Positive (Ph+) ALL, Relapsed/Refractory Philadelphia-Chromosome Positive (Ph+) ALL, and Philadelphia-Chromosome-Like Signature (Ph-Like) ALL With Known or Presumed Activating Dasatinib-Sensitive Mutations or Kinase Fusions (DSMKF)
Enrollment Status: Active, not recruiting
Publish Date: September 07, 2022
Intervention Type: Drug, Biological, Other
Study Drugs: BlinatumomabDasatinibMercaptopurineMethotrexateMethotrexate SodiumPrednisoneVincristineVincristine Sulfate
Study Phase: Phase 2
Randomized Phase II Study to Assess the Role of Nivolumab as Single Agent to Eliminate Minimal Residual Disease and Maintain Remission in Acute Myelogenous Leukemia (AML) Patients After Chemotherapy (REMAIN TRIAL)
Enrollment Status: Active, not recruiting
Publish Date: September 02, 2022
Intervention Type: Biological, Other
Study Drug: Nivolumab
Study Phase: Phase 2
A Phase I/II Multicenter Study Combining Guadecitabine, a DNA Methyltransferase Inhibitor, With Atezolizumab, an Immune Checkpoint Inhibitor, in Patients With Intermediate or High-Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia
Enrollment Status: Active, not recruiting
Publish Date: August 09, 2022
Intervention Type: Drug
Study Drugs: AtezolizumabGuadecitabine
Study Phase: Phase 1/Phase 2
Multicenter Phase 1/2 Study of Combination Therapy w/ DNA Methyltransferase Inhibitor Decitabine & Poly ADP Ribose Polymerase Inhibitor Talazoparib for Untreated AML in Adults Unfit for Cytotoxic Chemotherapy or R/R AML
Enrollment Status: Active, not recruiting
Publish Date: June 23, 2022
Intervention Type: Drug
Study Drugs: DecitabineTalazoparib
Study Phase: Phase 1/Phase 2
A Randomized, Open-label, Phase 2 Trial of Ponatinib in Patients With Resistant Chronic Phase Chronic Myeloid Leukemia to Characterize the Efficacy and Safety of a Range of Doses
Enrollment Status: Active, not recruiting
Publish Date: January 13, 2022
Intervention Type: Drug
Study Drug: Ponatinib
Study Phase: Phase 2
A Phase 1 Dose-Escalation Study of LAM-003 in Patients With Acute Myeloid Leukemia
Enrollment Status: Completed
Publish Date: December 20, 2021
Intervention Type: Drug
Study Phase: Phase 1
A Phase 1/2 Study of INCB053914 in Subjects With Advanced Malignancies
Enrollment Status: Terminated
Publish Date: December 08, 2021
Intervention Type: Drug
Study Drugs: INCB053914I-DAC (Intermediate Dose Cytarabine)AzacitidineRuxolitinib
Study Phase: Phase 1/Phase 2
An Open-label, Multi-center, Expanded Treatment Protocol of Midostaurin (PKC412) in Adult Patients With Newly Diagnosed Fms-like Tyrosine Kinase Receptor (FLT3) Mutated Acute Myeloid Leukemia (AML) Who Are Eligible for Standard Induction and Consolidation Chemotherapy.
Enrollment Status: No longer available
Publish Date: July 15, 2020
Intervention Type: Drug
Feasibility and Outcomes of Allogeneic Hematopoietic Cell Transplantation (HCT) Compared to Conventional Therapy for Older and Medically Infirm Patients Diagnosed With Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes: A Prospective Observational Study
Enrollment Status: Completed
Publish Date: November 15, 2019
Correlative Biomarker Study for MPD-RC Treatment Studies in the Philadelphia Chromosome Negative MPD
Enrollment Status: Completed
Publish Date: December 13, 2018
Single Arm Salvage Therapy With Pegylated Interferon Alfa-2a for Patients With High Risk Polycythemia Vera or High Risk Essential Thrombocythemia Who Are Either Hydroxyurea Resistant or Intolerant or Have Had Abdominal Vein Thrombosis
Enrollment Status: Completed
Publish Date: January 11, 2017
Intervention Type: Drug
Study Phase: Phase 2
Open Label, Phase II Dosing Study of Ara-C Chemotherapy in Combination With EL625 and Idarubicin in Refractory and Relapsed Acute Myelogenous Leukemia (AML)
Enrollment Status: Completed
Publish Date: September 18, 2014
Intervention Type: Drug
Study Phase: Phase 2
Phase III Study of MDR Modulation With PSC-833 (NSC #648265) Followed by Immunotherapy With rIL-2 (NSC #373364) vs. No Further Therapy in Previously Untreated Patients With AML >60 Years
Enrollment Status: Completed
Publish Date: June 04, 2013
Intervention Type: Drug
Study Phase: Phase 3
View 15 Less Clinical Trials -
197 Total Publications
AML-382 Cardiovascular Disease and Diabetes Mellitus Impact Outcomes of Patients With Acute Myeloid Leukemia.
Journal: Clinical lymphoma, myeloma & leukemia
Published: September 27, 2022
Save this doctor for later
Sign Up
Looking for the best doctor for you?
Start Here
Is this your doctor?
Find a second opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn more
Similar Doctors
AE
Dr. Ashkan Emadi
Hematology | Hematology Oncology
Highly rated in
20
conditions
Hematology
Hematology Oncology

University of Maryland Medical System

University Of Maryland Medical Center

22 S Greene St, 
Baltimore, MD 

Ashkan Emadi is a Hematologist and a Hematologist Oncology expert in Baltimore, Maryland. Emadi has been practicing medicine for over 27 years and is highly rated in 20 conditions, according to our data. His top areas of expertise are Acute Myeloid Leukemia (AML), Acute Myeloblastic Leukemia with Maturation, Acute Myeloblastic Leukemia without Maturation, Bone Marrow Aspiration, and Bone Marrow Transplant. He is licensed to treat patients in Maryland. Emadi is currently accepting new patients.

RB
Dr. Robert A. Brodsky
Hematology | Oncology
Highly rated in
31
conditions
Hematology
Oncology

Johns Hopkins Health System

Johns Hopkins University

600 N Wolfe St, 
Baltimore, MD 
 1.9 mi

Robert Brodsky is a Hematologist and an Oncologist in Baltimore, Maryland. Brodsky has been practicing medicine for over 34 years and is highly rated in 31 conditions, according to our data. His top areas of expertise are Paroxysmal Nocturnal Hemoglobinuria (PNH), Paroxysmal Cold Hemoglobinuria, Hemolysis, Anemia, and Bone Marrow Transplant. He is licensed to treat patients in Maryland. Brodsky is currently accepting new patients.

IG
Dr. Ivana N. Gojo
Hematology Oncology | Hematology | Oncology
Highly rated in
22
conditions
Hematology Oncology
Hematology
Oncology

Johns Hopkins Health System

Johns Hopkins Sidney Kimmel Comprehensive Cancer Center

Baltimore, MD 
 1.8 mi

Ivana Gojo is a Hematologist Oncology specialist and a Hematologist in Baltimore, Maryland. Gojo has been practicing medicine for over 31 years and is highly rated in 22 conditions, according to our data. Her top areas of expertise are Acute Myeloid Leukemia (AML), Acute Myeloblastic Leukemia with Maturation, Acute Myeloblastic Leukemia without Maturation, Bone Marrow Transplant, and Bone Marrow Aspiration. She is licensed to treat patients in Maryland. Gojo is currently accepting new patients.